Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Enfortumab Vedotin in Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05014139Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Dec 2021
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of enfortumab vedotin in non-muscle-invasive bladder cancer (NMIBC) (2 cohorts), sponsored by Astellas Pharma. Primary endpoints: Adverse Events at 1 year, Laboratory Abnormalities at 1 year and 1 more. Started Dec 2021; status: terminated.
02
Drugs
enfortumab vedotin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05014139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014139.